These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680 [TBL] [Abstract][Full Text] [Related]
9. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Böger RH Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822 [TBL] [Abstract][Full Text] [Related]
10. The clinical significance of asymmetric dimethylarginine. Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705 [TBL] [Abstract][Full Text] [Related]
11. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Baylis C Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427 [TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes. Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528 [TBL] [Abstract][Full Text] [Related]
13. Association of asymmetric dimethylarginine and endothelial dysfunction. Böger RH Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027 [TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Liu X; Xu X; Shang R; Chen Y Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990 [TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Ueda S; Yamagishi S; Kaida Y; Okuda S Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585 [TBL] [Abstract][Full Text] [Related]
17. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Yamagishi S; Ueda S; Okuda S Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960 [TBL] [Abstract][Full Text] [Related]
18. ADMA: its role in vascular disease. Cooke JP Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864 [TBL] [Abstract][Full Text] [Related]